Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.

Ehsan Moazen-ZadehSamaneh BayanatiKimia ZiafatFarzin RezaeiBita MesgarpourShahin Akhondzadeh

Published in: Journal of psychopharmacology (Oxford, England) (2020)

This is the first study to provide evidence for the therapeutic effect of vortioxetine on negative symptoms as an adjunctive to treatment with antipsychotics in patients with schizophrenia.

Keyphrases

double blind
clinical trial
placebo controlled
major depressive disorder
study protocol
phase ii
bipolar disorder
phase iii
randomized controlled trial
stem cells
phase ii study
physical activity
mesenchymal stem cells
sleep quality
rectal cancer
smoking cessation